Google is planning to give new businesses including its growing Life Sciences division ample breathing room as part of its reorganization, allowing the startups to run more independently as the tech titan rejigs operations and creates its parent company, Alphabet.
Siemens remains on track to redefining its Healthcare division as a separate business. On its way, the international conglomerate has picked up David Pacitti, a former SVP of Abbott Vascular in the U.S., to head up its North American Healthcare business.
A patent filing reveals that Apple is developing a ring computing device. Worn on the finger, the gizmo is expected to house technology that includes biometric sensors for monitoring cardiac rhythm and perspiration.
A group of bioengineers have developed a noninvasive, portable device that resembles a finger-worn, pulse oximeter to count white blood cells. They have three workable prototypes that are being tested with chemotherapy patients to track their immune system in real-time. The researchers aim to have an initial beta product that it can support via crowdfunding in 2017, with a product on the market potentially in 2019.
UPS announced the opening of a 200,800-square-foot distribution and warehousing facility in New Jersey that's aimed at meeting the special needs of medical device manufacturers.
As scientists explore the genetic underpinnings of disease to help develop new diagnostics and treatments, an NIH-backed team of researchers is creating the world's largest database of human genomic variation aimed at clinical use.
Medtronic is rolling out its upgraded, Bluetooth-enabled wearable device, the Verify Evaluation System. It's for the selection of patients who will benefit from the company's neuromodulation implant to treat chronic overactive bladder or bowel incontinence.
Apple has been gaining momentum for its ResearchKit since rolling out the platform earlier this year, with the first batch of studies using the product recording high rates of enrollment for sponsors. The platform's success caught the eye of Yale University scientists, who are planning to use ResearchKit for a study of heart problems in children and adults.
Tiny OTC-traded micro-cap Avita Medical has won backing from the U.S. Biomedical Advanced Research and Development Authority (BARDA) of its PMA approval trial for its ReCell burn treatment device. It will get $16.9 million upfront for the study and for procurement of more than 5,000 of the devices. The ongoing pivotal trial is expected to complete enrollment by the end of the this year.
Royal Philips and the Massachusetts Institute of Technology have teamed up to develop a noninvasive means of measuring intracranial pressure to detect brain injuries. It's expected to incorporate Philips' ultrasound technology and MIT's physiological modeling.
Ireland's Neuravi is the latest entrant into the accelerating market for stent retriever devices to treat stroke by physically removing blood clots in the brain. Following a limited launch, the company announced that it has ramped up the availability of its EmboTrap Revascularization Device throughout Europe.
Genomics England has hired Boston biotech Berg to help it accomplish its mission to sequence 100,000 genomes.
Fertility company OvaScience saw its shares drop by more than half after a Sept. 28 announcement that it would not meet its stated goal of 1,000 Augment procedures in 2015. The company chalks this up to an expanding commercial operation, as well as recent M&A activity in key commercial in vitro fertilization clinics where the treatment is offered.
2014 Fierce 15 member EarLens just obtained an FDA approval of its hearing aid via the rarely used de novo pathway for low- to moderate-risk devices that don't have a substantially equivalent predecessor on the market.
InnFocus has nabbed a pair of strategic ophthalmic investors in its Series C financing for $32.8 million. The cash infusion will go to the final phase of clinical testing for the startup's MicroShunt, which is expected to be a minimally invasive alternative to surgery for primary open angle glaucoma.
Royal Philips has grand plans for growth in Israel. CEO Frans Van Houten opened up to Israeli newspaper Globes about the company's med tech ambitions in the country, months after Philips kicked off operations for a new technology incubator in Israel with partner Teva Pharmaceutical Industries.
Faced with a challenge from activist investor Third Point, Baxter has opted to try to placate rather than resist. The pair first started wrangling publicly in early August when the firm disclosed a 10% stake in the company in an open letter requesting two board seats.
2014 Fierce 15 member Oraya Therapeutics seeks to reduce the number of eye injections required to treat wet age-related macular degeneration, the leading cause of blindness in the developed world. Its CE-marked X-ray device safely delivers radiation to the back of the eye, improving the efficacy of anti-VEGF injectable eye drugs like Genentech's Lucentis.
C.R. Bard will acquire the outstanding shares of a Japan-based joint venture that it has been invested in for about 40 years with Kobayashi Pharmaceutical, Medicon. The New Jersey-based med tech will acquire Kobayashi's 50% ownership stake for a total of 11.2 billion yen ($93.2 million) doled out over the next 10 years. The purchase is expected to give Bard more of a foothold in the Japanese market.
UVLrx Therapeutics has secured a CE mark for its intravenous UV light therapeutic system across a wide variety of indications. The use of ultraviolet blood irradiation stretches back over a century, but fell out of favor with the rise of antibiotics in the 1950s. This system, dubbed UVLrx 1500, is designed to be used without removing the blood from the body.